{"id":3802,"date":"2025-05-05T17:54:31","date_gmt":"2025-05-05T14:54:31","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3802"},"modified":"2025-05-05T17:55:03","modified_gmt":"2025-05-05T14:55:03","slug":"scribe-therapeutics-and-prevail-therapeutics-to-share-in-vivo-crispr-based-genome-editing-data-at-asgct-2025","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/es\/scribe-therapeutics-and-prevail-therapeutics-to-share-in-vivo-crispr-based-genome-editing-data-at-asgct-2025\/","title":{"rendered":"Scribe Therapeutics y Prevail Therapeutics compartir\u00e1n datos de edici\u00f3n gen\u00f3mica in vivo basados en CRISPR en ASGCT 2025"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Scribe Therapeutics, una empresa de medicamentos gen\u00e9ticos que libera el potencial de CRISPR para transformar la salud humana, anunci\u00f3 hoy su participaci\u00f3n en la 28.\u00aa Reuni\u00f3n Anual de la Sociedad Estadounidense de Terapia G\u00e9nica y Celular (ASGCT), que tendr\u00e1 lugar del 13 al 17 de mayo de 2025 en el Centro de Convenciones Ernest N. Morial en Nueva Orleans, Luisiana.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Scribe Therapeutics ofrecer\u00e1 dos presentaciones que mostrar\u00e1n los avances continuos de la compa\u00f1\u00eda posibles gracias a su enfoque CRISPR para dise\u00f1ar nuevos medicamentos gen\u00e9ticos in vivo.<\/strong> En una demostraci\u00f3n de potente aplicaci\u00f3n terap\u00e9utica, Scribe Therapeutics presentar\u00e1 nuevas estrategias de edici\u00f3n gen\u00f3mica utilizando su tecnolog\u00eda X-Editor (XE) para atacar mutaciones en la distrofia muscular de Duchenne (DMD), un trastorno neuromuscular grave que puede provocar insuficiencia respiratoria y card\u00edaca. Los hallazgos de este estudio mostrar\u00e1n a XE como una plataforma eficaz y vers\u00e1til para el tratamiento de la DMD y otros trastornos musculares hereditarios.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La presentaci\u00f3n conjunta describir\u00e1 el trabajo de Scribe Therapeutics y Prevail Therapeutics, una subsidiaria propiedad al 100 % de Eli Lilly and Company, para dise\u00f1ar vectores virales adenoasociados (AAV) autoinactivantes que incorporan la XE basada en CRISPR de Scribe Therapeutics con ARN gu\u00eda autodirigidos, y los resultados demuestran una edici\u00f3n in vivo potente, transitoria y controlable en el sistema nervioso central de ratones. Las compa\u00f1\u00edas alcanzaron recientemente un hito en su colaboraci\u00f3n para abordar enfermedades neurol\u00f3gicas y neuromusculares.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Leer m\u00e1s: <a href=\"https:\/\/dmdwarrior.com\/es\/new-gene-therapies-for-duchenne-muscular-dystrophy\/\">Nuevas terapias gen\u00e9ticas para la distrofia muscular de Duchenne<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Scribe Therapeutics, a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced its participation in the 28th American Society of Gene &amp; Cell Therapy (ASGCT) Annual Meeting taking place May 13-17, 2025, at the Ernest N. Morial Convention Center in New Orleans, LA. Scribe Therapeutics will deliver two presentations that [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3803,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[366,290,72,61,365,364,363],"class_list":["post-3802","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-asgct-2025","tag-crispr","tag-gene-editing","tag-gene-therapy","tag-genome-editing","tag-prevail-therapeutics","tag-scribe-therapeutics"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/3802","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/comments?post=3802"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/3802\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media\/3803"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media?parent=3802"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/categories?post=3802"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/tags?post=3802"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}